These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
465 related articles for article (PubMed ID: 5140093)
41. Comparison of amantadine, placebo, and levodopa in Parkinson's disease. Bauer RB; McHenry JT Neurology; 1974 Aug; 24(8):715-20. PubMed ID: 4858417 [No Abstract] [Full Text] [Related]
42. A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel). Merrick EM; Schmitt PP Curr Ther Res Clin Exp; 1973 Aug; 15(8):552-8. PubMed ID: 4200529 [No Abstract] [Full Text] [Related]
43. The therapeutic possibilities of L-dopa and amantadine in Parkinsonian patients who have undergone bilateral thalamotomy. Giuffrè R; Gambacorta D Eur Neurol; 1971; 5(5):311-6. PubMed ID: 4943872 [No Abstract] [Full Text] [Related]
44. [Action of amantadine in extrapyramidal syndromes caused by neuroleptics]. Fanali A; Nardini M; Sorgona F Sist Nerv; 1970; 22(5):273-85. PubMed ID: 5514245 [No Abstract] [Full Text] [Related]
45. [Current medical treatment of Parkinsonian syndromes]. Cincă I; Bulandra R; Serbănesco A; Ninosu N Rev Roum Neurol; 1973; 10(4):257-85. PubMed ID: 4767886 [No Abstract] [Full Text] [Related]
46. [Therapy and problems of parkinsonism]. Albert E Nervenarzt; 1971 May; 42(5):225-41. PubMed ID: 4942900 [No Abstract] [Full Text] [Related]
50. [Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)]. Schneider E; Fischer PA; Jacobi P Med Klin; 1974 Mar; 69(13):541-5. PubMed ID: 4831456 [No Abstract] [Full Text] [Related]
51. [Accomplishment of the treatment and evaluation of treatment alternatives in parkinsonism]. Presthus J Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2119. PubMed ID: 4773985 [No Abstract] [Full Text] [Related]
52. [Iron, transferrin, copper and ceruloplasmin of the serum and cerebrospinal fluid in extrapyramidal diseases and primary myopathies. Study in basic conditions and in Parkinsonism after treatment with dopaminergic agents (L-dopa, L-dopa + RO 4-4602, amantadine)]. Campanella G; Carrieri P; Romito D; Pasqual-Marsettin E Acta Neurol (Napoli); 1973; 28(1):1-34. PubMed ID: 4704396 [No Abstract] [Full Text] [Related]
53. [Quantitative testing methods for objectification of the effect of prolonged L-dopa therapy in parkinsonism]. Gerstenbrand F; Grünberger J; Schubert H Nervenarzt; 1973 Aug; 44(8):428-33. PubMed ID: 4733895 [No Abstract] [Full Text] [Related]
59. KR 339 in the treatment of Parkinsonian tremor. Iivanainen M Acta Neurol Scand; 1974; 50(4):469-77. PubMed ID: 4604665 [No Abstract] [Full Text] [Related]
60. The comparative value of amantadine and levodopa. Dallos V; Heathfield K; Stone P; Allen F Postgrad Med J; 1972 Jun; 48(560):354-8. PubMed ID: 4558895 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]